KR970705635A - 사람 케모킨 베타-9(Human chemokine beta-9) - Google Patents

사람 케모킨 베타-9(Human chemokine beta-9) Download PDF

Info

Publication number
KR970705635A
KR970705635A KR1019970701144A KR19970701144A KR970705635A KR 970705635 A KR970705635 A KR 970705635A KR 1019970701144 A KR1019970701144 A KR 1019970701144A KR 19970701144 A KR19970701144 A KR 19970701144A KR 970705635 A KR970705635 A KR 970705635A
Authority
KR
South Korea
Prior art keywords
polypeptide
polynucleotide
amino acid
seq
dna
Prior art date
Application number
KR1019970701144A
Other languages
English (en)
Inventor
하오동 리
마크 디 아담스
Original Assignee
벤슨 로버트 에이치
휴먼 게놈 사이언시즈, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23132551&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR970705635(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 벤슨 로버트 에이치, 휴먼 게놈 사이언시즈, 인코포레이티드 filed Critical 벤슨 로버트 에이치
Publication of KR970705635A publication Critical patent/KR970705635A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

사람 Ckβ-9 폴리펩타이드 및 이러한 케모킨 폴리펩타이드를 암호화하는 DNA(RNA) 및 재조합 기술에 의해 이러한 폴리펩타이드를 제조하는 방법이 기술되어 있다. 또한 백혈병, 종양, 만성 감염, 자가면적 질환, 섬유중 질환, 상처 치유 및 건선 치료시 이러한 Ckβ-9 폴리펩타이드를 이용하는 방법이 또한 기술되어 있다. 이러한 폴리펩타이드에 대한 길항제 및 류마치스 관절염, 자가면역 질환, 만성 염증성 질환 및 감염성 질환을 치료하기 위한 치료제로서의 이의 용도가 또한 기술되어 있다. Ckβ-9 암호화 서열중 돌연변이의 존재 및 Ckβ-9 단백질의 과-발현을 검출하는 진단 방법이 또한 기술되어 있다.

Description

사람 케모킨 베타 -9(Human chemokine beta-9)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 cDNA 서열을 도시한 것이며 이는 Ckβ-9의 유추된 아미노산 서열에 상응한다. 제2도는 Ckβ-9 과 에토탁신의 성숙한 펩타이드(하단)간의 아미노산 서열 상동성을 나타낸다.

Claims (20)

  1. (a) 서열 2에 설정된 바와 같은 -23번 아미노산에서 111번 아미노산까지를 포함하는 폴리펩타이드를 암호화하는 폴리뉴클레오타이드; (b) 서열2에 설정된 바와 같은 1번 아미노산에서 111번 아미노산까지를 포함하는 폴리펩타이드를 암호화하는 폴리뉴클레오타이드; (c) 상기 (a) 또는 (b)의 폴리뉴클레오타이드와 70% 이상의 동일하며 이에 하이브리드화할 수 있는 폴리뉴클레오타이드; 및 (d) 상기 (a), (b) 또는 (c)의 폴리뉴클레오타이드의 폴리뉴클레오타이드 단편으로 이루어진 그룹중에서 선택된 구성원을 포함하는 분리된 폴리뉴클레오타이드.
  2. 제1항에 있어서, DNA인 폴리뉴클레오타이드.
  3. 제2항에 있어서, 서열 2의 1번 아미노산에서 111번 아미노산까지를 포함하는 폴리펩타이드를 암호화하는 폴리뉴클레오타이드.
  4. (a) ATCC 기탁 번호 제75803호중에 포함된 DNA에의해 발현된 아미노산 서열을 갖는 성숙한 폴리펩타이드를 암호화하는 폴리뉴클레오타이드; (b) ATCC 기탁 번호 제75803호중에 포함된 DNA에 의해 발현된 아미노산 서열을 갖는 폴리펩타이드를 암호화하는 폴리뉴클레오타이드; (c) 상기 (a)의 폴리뉴클레오타이드; 및 (d) 상기 (a), (b) 또는 (c)의 폴리뉴클레오타이드의 폴리뉴클레오타이드 단편으로 이루어진 그룹중에서 선택된 구성원을 포함하는 분리된 폴리뉴클레오타이드.
  5. 제1항에 있어서, 서열 1에 설정된 바와 같은 1번 뉴클레오타이드에서 405번 뉴클레오타이드까지의 서열을 포함하는 폴리뉴클레오타이드.
  6. 제1항에 있어서, 서열 1에 설정된 바와 같은 70번 뉴클레오타이드에서 405번 뉴클레오타이드까지의 서열을 포함하는 폴리뉴클레오타이드.
  7. 제2항에 따른 DNA를 포함하는 벡터.
  8. 제7항에 따른 벡터를 사용하여 유전적으로 조작된 숙주 세포.
  9. 제8항에 따른 숙주 세포로부터 상기 DNA가 암호화한 폴리펩타이드를 발현시킴을 포함하는, 폴리펩타이드의 제조 방법.
  10. 제7항에 따른 벡터로 세포를 유전적으로 조작함을 포함하여, 폴리펩타이드를 발현시킬 수 있는 세포를 생산하는 방법.
  11. (i) 서열 2의 유추된 아미노산 서열을 갖는 성숙한 폴리펩타이드, 및 이의 단편, 동족체 및 유도체; 및 (ⅱ) ATCC 기탁번호 제75803호의 cDNA에 의해 암호화된 성숙한 폴리펩타이드, 및 이의 단편, 동족체 및 유도체로 이루어진 그룹중에서 선택된 구성원을 포함하는, 제1항에 따른 폴리뉴클레오타이드에 의해 암호화된 폴리펩타이드.
  12. 제11항에 있어서, 서열 2의 1번 아미노산에서 111번 아미노산까지를 포함하는 폴리펩타이드.
  13. 제11항에 따른 폴리펩타이드에 대한 수용체의 활성화를 억제하는 화합물.
  14. 제11항에 따른 폴리펩타이드에 대한 수용체의 활성화시키는 화합물.
  15. 제11항에 따른 폴리펩타이드의 치료학적 유효량을, Ckβ-9를필요로 하는 환자에게 투여함을 포함하여, 상기 환자를 치료하는 방법.
  16. 제15항에 있어서, 치료학적 유효량의 상기 폴리펩타이드가, 상기 폴리펩타이드를 암호화하는 DNA를 환자에게 제공하고 생체내에서 이러한 폴리펩타이드를 발현시킴에 의해 투여되는 방법.
  17. 제13항에 따른 화합물의 치료학적 유효량을, Ckβ-9 폴리펩타이드를 억제할 필요가 있는 환자에게 투여함을 포함하여, 상기 환자를 치료하는 방법.
  18. 제11항에 따른 폴리펩타이드를 암호화하는 핵산 서열중의 돌연변이를 결정함을 포함하여, 상기 폴리펩타이드의 저-발현(under-expression)과 관련된 질병 자체 또는 이러한 빌병에 걸리기 쉬운지의 여부를 진단하는 방법.
  19. 숙주로부터 기원한 샘플중에서 제11항에 따른 폴리펩타이드의 존재를 분석함을 포함하는 진단 방법.
  20. 수용체에 대한 결합을 허용하는 조건하에서, 분석적으로 검출가능한 화합물을, 이 화합물과의 결합에 반응하여 검출가능한 시그날을 제공할 수 있는 제2성분과 얀합된, 폴리펩타이드에 대한 수용체를 자체의 표면상에서 발현하는 세포와 접촉시키는 단계; 및 상기 화합물과 수용체의 상호작용으로부터 생성되는 시그날의 부재 또는 존재 여부를 검정하는 단계를 포함하는, 제11항의 폴리펩타이드에 대한 효능제 화합물 또는 길항제 화합물을 동정하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019970701144A 1994-08-23 1995-06-06 사람 케모킨 베타-9(Human chemokine beta-9) KR970705635A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29425194A 1994-08-23 1994-08-23
US08/294,251 1994-08-23
PCT/US1995/006260 WO1996006169A1 (en) 1994-08-23 1995-06-06 Human chemokine beta-9

Publications (1)

Publication Number Publication Date
KR970705635A true KR970705635A (ko) 1997-10-09

Family

ID=23132551

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970701144A KR970705635A (ko) 1994-08-23 1995-06-06 사람 케모킨 베타-9(Human chemokine beta-9)

Country Status (14)

Country Link
US (3) US6518046B1 (ko)
EP (1) EP0799311B1 (ko)
JP (2) JPH10505493A (ko)
KR (1) KR970705635A (ko)
AT (1) ATE290080T1 (ko)
AU (1) AU708558B2 (ko)
CA (1) CA2198206A1 (ko)
DE (1) DE69534044T2 (ko)
DK (1) DK0799311T3 (ko)
ES (1) ES2235172T3 (ko)
MX (1) MX9701330A (ko)
NZ (1) NZ288799A (ko)
PT (1) PT799311E (ko)
WO (1) WO1996006169A1 (ko)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391589B1 (en) 1994-08-23 2002-05-21 Human Genome Sciences, Inc. Human chemokine beta-10 mutant polypeptides
US6174995B1 (en) 1994-08-23 2001-01-16 Haodong Li Human chemokines, CKβ4 and CKβ10/MCP-4
US6458349B1 (en) 1995-06-02 2002-10-01 Human Genome Sciences, Inc. Chemokine β-4 polypeptides
US7005509B1 (en) 1995-02-17 2006-02-28 Incyte Corporation Chemokine PANEC-1 polynucleotides and compositions and methods related thereto
US6290948B1 (en) 1996-05-14 2001-09-18 Smithkline Beecham Corporation Method of treating sepsis and ARDS using chamohine beta-10
AU4592397A (en) * 1996-10-02 1998-04-24 Schering Corporation Mammalian chemokines
AU5496798A (en) * 1997-01-20 1998-08-07 Shionogi & Co., Ltd. Human cc chemokine slc
WO1998056818A1 (en) * 1997-06-11 1998-12-17 Genetics Institute, Inc. Human l105 proteins and polynucleotides encoding same
US6084071A (en) * 1997-06-11 2000-07-04 Genetics Institute Human L105 polypeptides and polynucleotides encoding same
US6153441A (en) * 1998-02-17 2000-11-28 Smithkline Beecham Corporation Methods of screening for agonists and antagonists for human CCR7 receptor and CKβ-9 ligand and interaction thereof
JP2002533402A (ja) * 1998-12-31 2002-10-08 カイロン コーポレイション 癌を処置するためおよび樹状細胞の走化性を媒介するための方法
JP2003516324A (ja) 1999-11-24 2003-05-13 シェーリング コーポレイション 転移を阻害する方法
US6949243B1 (en) 1999-11-24 2005-09-27 Schering Corporation Methods of inhibiting metastasis
WO2002085286A2 (en) * 2001-04-18 2002-10-31 The Regents Of The University Of California Methods of using secondary lymphoid organ chemokine to modulate physiological processes in mammals
US20020168358A1 (en) * 2001-04-30 2002-11-14 Gladue Ronald P. Treatment of T-cell mediated diseases
WO2003092597A2 (en) 2002-05-01 2003-11-13 Human Genome Sciences, Inc. Antibodies that specifically bind to chemokine beta-4
US8795668B2 (en) * 2005-12-23 2014-08-05 The Regents Of The University Of Michigan Methods for treating pulmonary fibrosis
US9012419B2 (en) * 2006-05-17 2015-04-21 University Of Utah Research Foundation Methods and compositions related to eosinophil regulation
KR101919170B1 (ko) 2010-11-19 2018-11-15 에자이 알앤드디 매니지먼트 가부시키가이샤 중화 항-ccl20 항체

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2091266A1 (en) 1990-09-14 1992-03-15 Patricia Tekamp-Olson Expression of macrophage inducible proteins (mips) in yeast cells
US7005509B1 (en) 1995-02-17 2006-02-28 Incyte Corporation Chemokine PANEC-1 polynucleotides and compositions and methods related thereto

Also Published As

Publication number Publication date
EP0799311B1 (en) 2005-03-02
DK0799311T3 (da) 2005-07-11
CA2198206A1 (en) 1996-02-29
US7198944B2 (en) 2007-04-03
EP0799311A1 (en) 1997-10-08
WO1996006169A1 (en) 1996-02-29
NZ288799A (en) 1999-06-29
EP0799311A4 (en) 1998-09-30
US20050244888A1 (en) 2005-11-03
US20060040313A1 (en) 2006-02-23
MX9701330A (es) 1998-02-28
AU708558B2 (en) 1999-08-05
JPH10505493A (ja) 1998-06-02
PT799311E (pt) 2005-05-31
ATE290080T1 (de) 2005-03-15
DE69534044D1 (de) 2005-04-07
ES2235172T3 (es) 2005-07-01
DE69534044T2 (de) 2005-12-29
US7097985B2 (en) 2006-08-29
AU2814195A (en) 1996-03-14
US6518046B1 (en) 2003-02-11
JP2003047492A (ja) 2003-02-18

Similar Documents

Publication Publication Date Title
KR970705635A (ko) 사람 케모킨 베타-9(Human chemokine beta-9)
DK176181B1 (da) Et rekombinant oplöseligt fragment af alfa-subenhedpolypeptidet af human mastcelle IgE overfladereceptor samt anvendelse af samme
KR970701776A (ko) 형질전환 성장 인자 알파 에이치1(Transforming growth factor alpha H1)
KR970707141A (ko) 종양 괴사 인자-감마(Tumor necrosis factor-gamma)
EP0814158A3 (en) Human C3a receptor variant; uses in diagnostics and therapeutics
KR970705405A (ko) 사람 케모킨 폴리펩타이드(Human Chemokine Polypeptides)
AU724547B2 (en) Autoantigen and proteins structurally related thereto for use in immunotherapy of autoimmune diseases
NZ279963A (en) Human tissue inhibitor of metalloproteinase-4 (timp-4) and dna (rna) encoding polypeptide which may be derived from atcc 75946
CA2067744A1 (en) The human c3b/c4b receptor (cr1)
KR970700438A (ko) 마크로파지 염증성 단백질-3,-4 및 -1감마(MACROPHAGE INFLAMMATORY PROTEINS -3,-4 AND -1sg(g))
CA2247285A1 (en) Human tumor necrosis factor delta and epsilon
ATE442385T1 (de) Interleukin-17 rezeptor-ähnliches protein
ZA892397B (en) The human c3b/c4b receptor(cr1)
NZ332318A (en) Chemokine alpha 2 and it's therapeutic and diagnostic use in treating illnesses
WO1998006841A3 (en) Two human nsp-like proteins
EP0812913A3 (en) HR-1 receptor, a receptor of the cytokine receptors family
KR970704887A (ko) 혈청 파라옥소나제
KR970701724A (ko) 스타니어스 단백질인 스타니오칼신의 소체(Corpuscles of stannius protein, stanniocalcin)
EP0834568A3 (en) Novel saliva binding protein
EA005973B1 (ru) Применение sarp-1 для лечения и/или предупреждения склеродермии
WO2002030979A3 (en) Polypeptides homologous to thymosin, ephrin a receptors, and fibromodulin, and polynucleotides encoding same
CA2215350A1 (en) Transforming growth factor alpha hii
US7335350B2 (en) Chemokines mutants having improved oral bioavailability
KR970707155A (ko) 사람 스탄니오칼신-알파(Human stanniocalcin-alpha)
WO2002030974A2 (en) Proteins and nucleic acids encoding same

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application